Adviser Investments LLC Has $8.46 Million Position in Merck & Co., Inc. (NYSE:MRK)

Adviser Investments LLC lifted its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,771 shares of the company’s stock after purchasing an additional 3,033 shares during the period. Adviser Investments LLC’s holdings in Merck & Co., Inc. were worth $8,458,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Joseph P. Lucia & Associates LLC bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $25,000. Landmark Wealth Management LLC bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $25,000. Front Row Advisors LLC boosted its stake in Merck & Co., Inc. by 89.4% in the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares during the last quarter. Okabena Investment Services Inc. bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Finally, Western Pacific Wealth Management LP bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 73.33% of the company’s stock.

Merck & Co., Inc. Stock Up 3.5 %

Merck & Co., Inc. stock opened at $87.51 on Friday. The firm has a market capitalization of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. The company’s 50-day moving average is $88.83 and its 200-day moving average is $87.81. Merck & Co., Inc. has a fifty-two week low of $71.50 and a fifty-two week high of $95.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The business had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 42.27%.

Analyst Ratings Changes

A number of brokerages have issued reports on MRK. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $100.00 in a research note on Wednesday, September 14th. SVB Leerink lifted their price target on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the stock an “outperform” rating in a research report on Monday, September 12th. Erste Group Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $89.00 to $102.00 in a research report on Wednesday, July 6th. Finally, Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.28.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.